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Introduction
Membrane-derived microvesicles (MVs) include a range of 
extracellular  vesicles,  including  exosomes,  microparticles, 
and shed MVs secreted by many cell types under both normal 
physiological  and  pathological  conditions.1  As  intercellular 
communication tools, MVs have been reported to have roles 
in a wide range of cellular functions: immunological modula-
tion, coagulation, and tumor progression, including angiogen-
esis and metastasis.2,3 Additionally, they have been reported 
to serve as vehicles for transferring cargo (mRNA, miRNA, 
noncoding RNAs, proteins, and oncogenes) between cells.4–8 
The mRNA content in MVs open new research opportuni-
ties from cancer diagnostics to gene therapy applications.9–12 
Despite, the intensive research in analyzing the RNA content 
of MVs, it remains unclear how RNAs are directed to MVs.
Mechanistically, cis-acting regulatory sequences and trans-
acting proteins are considered as the main driving forces of 
mRNA localization within cells and have an important role 
in  post-transcriptional  regulation.  Such  sequences,  also 
known as zipcodes, are typically found in the 3′-untranslated 
regions (3′UTRs) of mRNA transcripts and mediate binding 
of a ribonuclear protein complex to the mRNA which tem-
porarily  blocks  its  translation  and  mediates  movement  via 
the cytoskeleton to a cellular location where it releases the 
mRNA and translation commences.13,14
In addition to zipcodes, microRNAs (miRNAs) also have 
a  critical  role  in  post-transcriptional  regulation  of  mRNAs. 
miRNAs  are  small,  noncoding,  single-stranded  RNA  mol-
ecules  (~21–23-nucleotides  (nt)  long)  that  regulate  levels 
of gene expression in many organisms.15 miRNAs mediate 
post-transcriptional regulation in three ways, by mRNA deg-
radation,  mRNA  destabilization  via  deadenylation,  and 
translational repression.16 In addition to negative regulation, 
miRNAs have also been reported to function in the activa-
tion of translation in some cases.17 Although zipcodes and 
miRNA target sequences are both found in the 3′UTRs of the 
mRNA transcripts, there has been no report of cooperation 
between these two regulatory mechanisms in mRNA fate.
In this study, we investigated whether there is a sequence 
in the 3′UTR of a subset of mRNAs that are enriched in MVs 
which may act like a zipcode to target them into MVs. Our 
multiple sequence alignment analysis comparing the cellu-
lar transcriptome of human primary glioblastoma multiforme 
(GBM)  cells  with  the  transcriptome  of  MVs  derived  from 
them,5 revealed a stem loop-forming sequence of 25 nt, varia-
tions of which were present in some of the most MV-enriched 
mRNAs. This putative zipcode sequence contained a single 
miRNA-binding site for miR-1289, as well as a CTGCC core 
sequence. Mutational analysis showed that these sequences 
cooperated in enrichment of a reporter mRNA in MVs and 
that upregulation of miR-1289 levels in cells further enhanced 
MV enrichment.
Results
Microarrays of the mRNAs isolated from GBM-derived 
MV reveals a zipcode-like sequence. To test the hypoth-
esis that there is a sequence in the 3′UTR of mRNAs that 
are enriched in MVs which serves as a zipcode to target 
them to MVs, we analyzed microarray studies of the RNA 
content of two human primary GBM cells and two primary 
miR-1289 and “Zipcode”-like Sequence Enrich mRNAs  
in Microvesicles
Mehmet Fatih Bolukbasi1, Arda Mizrak1, Gokhan Baris Ozdener1, Sibylle Madlener2, Thomas Ströbel3, Erdogan Pekcan Erkan2,  
Jian-Bing Fan4, Xandra O Breakefield1 and Okay Saydam2
Despite intensive studies, the molecular mechanisms by which the genetic materials are uploaded into microvesicles (MVs) are 
still unknown. This is the first study describing a zipcode-like 25 nucleotide (nt) sequence in the 3′-untranslated region (3′UTR) 
of mRNAs, with variants of this sequence present in many mRNAs enriched in MVs, as compared to their glioblastoma cells 
of origin. When this sequence was incorporated into the 3′UTR of a reporter message and expressed in a different cell type, it 
led to enrichment of the reporter mRNA in MVs. Critical features of this sequence are both a CUGCC core presented on a stem-
loop structure and a miRNA-binding site, with increased levels of the corresponding miRNA in cells further increasing levels 
of mRNAs in MVs.
Molecular Therapy–Nucleic Acids (2012) 1, e10; doi:10.1038/mtna.2011.2; published online 7 February 2012Molecular Therapy–Nucleic Acids
mRNA Zipcode in Microvesicle Biology
Bolukbasi et al
2
melanomas, and MVs derived from them. We focused on 
the 20 mRNAs most enriched in MVs as compared to cells 
of origin (Supplementary Table S1) and performed exten-
sive analysis of 3′UTR sequences of these mRNAs using a 
multiple alignment program (Clustal W2-http://www.clustal.
org/). Among those 20 transcripts, NM_003614.1 (mRNA 
GalR3) gave the highest pairwise alignment score within 
the list. Hence, we decided to evaluate the 25-nt sequence 
of this transcript with the highest consensus among these 
enriched mRNAs   (Figure 1). The similarities between this 
25-nt sequence and the 3′UTR sequences of the top 20 
MV-enriched transcripts was later deciphered with BLAST 
pairwise alignment. Within the conserved regions, 25 nt are 
picked for further ClustalW alignment which resulted in a 
5-nt core sequence “CTGCC” (or variations CTGC, CTCCC, 
CGCCC, TGCC) shown in a red rectangle in 11 of these 20 
MV-enriched mRNAs (Figure 2).
Zipcode fused to the EGFP mRNA is functional. To exam-
ine the possible effect of this 25-nt sequence on incorpo-
ration of mRNA molecules into MVs, we incorporated this 
sequence into the pEGFP-N1 plasmid (Clontech, Mountain 
View, CA) by removing most of the original 3′UTR sequence 
of the enhanced green fluorescent protein (EGFP) mRNA. 
The  resulting  plasmid  expresses  EGFP  mRNA  fused  to 
this potential zipcode, followed by a polyA addition site and 
referred to here as pEGFP-N1-3UTR-25nt. Intact pEGFP-N1 
plasmid was used as a control. We first tested whether the new 
EGFP mRNA was stable without its original 3′UTR. Human 
embryonic kidney-293T (HEK-293T) cells were transfected 
with either wild-type EGFP-expressing plasmid pEGFP-N1 
or pEGFP-N1-3UTR-25nt. Twenty-four hours later, total RNA 
was isolated from cells and quantitative reverse transcrip-
tion qRT-PCR was performed for EGFP mRNA. As shown 
in Figure 3a, we observed a similar increased accumulation 
of  the  EGFP  mRNA  24  hours  after  transfection  with  both 
pEGFP-N1 and pEGFP-N1-3UTR-25nt constructs. To evalu-
ate whether the EGFP mRNA fused to the “25-nt sequence” 
was efficiently translated into EGFP protein, we also exam-
ined  these  transfected  cells  by  fluorescence  microscopy. 
As shown in Figure 3b,c, similar EGFP protein expression 
levels  were  observed  for  pEGFP-N1  (lanes  1  and  2)  and 
pEGFP-N1-3UTR-25nt (lanes 3 and 4) over time suggest-
ing that 25-nt long sequence is compatible with stability and 
efficient translation.
We next tested whether this 25-nt sequence might be suffi-
cient for enrichment of EGFP mRNA’s in MVs. We transfected 
HEK-293T cells either with control plasmid or pEGFP-N1-
3UTR-25nt and 72 hours later, we harvested MVs and cells 
and performed qRT-PCR for EGFP and GAPDH mRNAs. We 
observed that this sequence increased the amount of EGFP 
mRNA in MVs by about twofold, as compared with the original 
construct (Figure 4a). We also tested whether the presence 
of the 5-nt core sequence “CTGCC” is required for enrich-
ment. When we mutated the 5-nt core sequence in two differ-
ent ways, namely MT1 and MT2 (Figure 4b, Supplementary 
Figure S1 and S2), mRNA enrichment inside the MVs was 
inhibited   (Figure 4c). To avoid any plasmid DNA contamina-
tion during MV isolation, samples were treated with DNase 
before qRT-PCR, confirming that the data observed is due 
to mRNA content in MVs (Supplementary Figure S3a,b). 
Moreover, to investigate the origin of the signal received by 
qPCR, we performed the following treatments: DNaseI on 
the outside of MVs and content of MVs, and RNase treat-
ment before and after RNA isolation from MVs. As shown in 
Supplementary Figure S3c, DNaseI treatment did not pre-
vent amplification of the PCR product, whereas after RNase 
treatment of the contents of MVs, no signal was observed 
suggesting that the signal observed in our experimental con-
ditions came from mRNAs isolated from inside of the MVs 
not from any plasmid DNA contamination during MVs isola-
tion or mRNAs attachment to the MVs.
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Figure 1  Alignment of the 3′UTRs of top 20 enriched transcript. 3′UTR sequences of the top 20 enriched transcripts were obtained 
from National Center for Biotechnology Information (NCBI) and Ensemble databases. The sequences were aligned with ClustalW a mul-
tiple sequence alignment program. The 25-nt sequence we used in this study and refer as the zipcode is shown in the red rectangle. nt, 
nucleotide; UTR, untranslated region.www.moleculartherapy.org
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miR-1289 directly binds to 25-nt zipcode and, in part, 
has  a  cooperative  role  in  the  enrichment  of  mRNAs 
within MVs. We further investigated the role of the miRNA-
binding sequence in the 3′UTR region of the reporter mRNA 
in transfer of the EGFP-25nt mRNA into MVs. Based on the 
facts that miRNAs are a family of 19–24 nt noncoding RNAs 
that inhibit the expression of target mRNAs by binding to 
complementary sequences in the UTRs of mRNAs (typically 
the 3′UTR) and repressing translation and/or cleaving the 
mRNA, we hypothesized that an miRNA might be involved 
in this MV targeting mechanism. To test this hypothesis, we 
performed  miRNA  database  search  (http://www.mirbase.
org/) within the 25-nt putative zipcode sequence and found 
a  potential  binding  site  for  miR-1289  (Figure  5a).  Strik-
ingly,  when  we  co-transfected  cells  with  the  EGFP-25nt 
cassette and pre-miR-1289, MV enrichment of the mRNA 
increased to sixfold, whereas when we silenced endogenous 
miR-1289 by transfection with its anti-miR-1289 sequence, 
we  observed  inhibition  of  EGFP-25nt  mRNA  enrichment 
within MVs (Figure 5b). In these experimental conditions, 
after  transfection  of  pre-miR-1289,  miR-1289  levels  were 
increased ~100-fold in cells and 40-fold in MVs as assessed 
by  qRT-PCR,  while  endogenous  miR-1289  levels  in  cells 
were below the detection level of RT-PCR after inhibition of 
miR-1289 by anti-miR-1289 (data not show). The miR-1289-
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Figure 2  Deep alignment of the 3′UTR of the top 20 enriched 
transcripts.  The  similarities  between  the  25-nt  sequence  and 
the 3′UTR sequences of top 20 transcripts were deciphered with 
BLAST pairwise alignment. Within the conserved regions, a 25-nt 
sequence was picked for further ClustalW alignment. The 5-nt core 
sequence “CTGCC” is shown in the red rectangles. nt, nucleotide; 
UTR, untranslated region.
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mediated enrichment process is not due to the excessive 
expression of it either in HEK-293T or primary GBM cells, 
because miR-1289 was found to be expressed in low levels 
in those cells (data not shown). We further tested the role 
of the potential miR-1289 binding sequence in MV targeting 
of the mRNA by generating point mutations within the miR-
1289 target sequence (Supplementary Figure S2; MT3 and 
MT4) and observed that a mutation in the miR-1289 binding 
site (MT4) led to significant reduction in the accumulation 
of the EGFP-25nt mRNAs in MVs (Figure 5c). The finding 
that the MT3 mutation did not dramatically inhibit the accu-
mulation of the EGFP mRNA in MVs suggests that not only 
the miR-1289 binding site, but also the intact core sequence 
within  the  stem-loop  structure  are  involved  in  miR-1289-
meditated transfer of mRNAs into MVs.
To  test  whether  miR-1289  directly  binds  to  this  25-nt 
sequence,  we  constructed  pMir-Reporter  plasmids  carrying 
either the wild-type 25-nt zipcode or a zipcode with mutations 
in the core-binding site of miR-1289. The same mutations were 
introduced into pMir-Reporter vectors as in MT4 (Supplemen-
tary Figure S2). Co-transfection of the wild-type pmiR-zipcode 
and pre-miR-1289 resulted in significantly decreased luciferase 
activity  as  compared  with  transfection  with  pre-control  1, 
whereas transfection with the MT4 mutated sequence did not 
affect activity levels (Figure 5d). In order to test whether miR-
1289 overexpression could affect MV incorporation of endog-
enous mRNAs, we picked two mRNAs from Supplementary 
Table S1 based on their miR-1289 binding status and per-
formed similar experiments as in Figure 5b for GALR3 (one 
miR-1289 binding site in the 3′UTR) and MDK (no miR-1289 
binding site) mRNAs and found that miR-1289 expression sig-
nificantly increased GALR3 mRNA ratio (MVs/cell) by ~50%, 
as compared to pre control 1, whereas miR-1289 had no effect 
on the level of MDK mRNA in MVs (Figure 5e). These data 
suggest that miR-1289-mediated enrichment via the zipcode 
sequence functions for endogenous mRNAs as well.
Next, we looked for the presence of miR-1289 target sites 
within 3′UTRs of the top 50 enriched mRNAs, and found that 
14 of these mRNAs exhibited computationally predicted tar-
get sequences in their 3′UTR (Supplementary Table S2). 
To test whether decreased uptake of the reporter mRNA with 
a mutant zipcode into MVs was due to increased degrada-
tion of mRNA within cells, we also performed RT-PCRs for 
the cellular EGFP mRNA. As shown in Figure 6a, there was 
no significant difference in levels of mutant and wild-type 
EGFP mRNAs in cells over a 48-hour period of time. In addi-
tion, in cells co-transfected with pre-miR-1289 and pEGFP-
N1-3UTR-25nt, EGFP expression was not downregulated 
indicating that there was no inhibition of translation in these 
conditions (Figure 6b). qRT-PCR also showed that cellular 
mRNA levels of pEGFP-N1 3′UTR-25nt were not altered 
compared to control vector (Figure 6c). Taken together, our 
data suggested that miR-1289 does not inhibit translation of 
the EGFP-N1 3′UTR-25nt mRNA, but rather may provide a 
means of novel posttranscriptional gene silencing mecha-
nism by mediating the transfer of this mRNA into MVs.
Our  MV  mRNA  enrichment  assay  findings  suggest  that 
the  presence  of  both  the  core  “CTGCC”  region  and  the 
  miR-1289 binding site promote targeting of mRNA into MVs. 
To determine the extent to which these two elements are 
present within enriched and reduced sets of mRNAs in MVs, 
we searched the 3′UTR sequences of the top 50 enriched 
and 50 reduced mRNAs in MVs, as compared to GBM cells 
for the presence of these elements. Surprisingly, among the 
enriched mRNAs set, the presence of both elements had 
more than twice the frequency as among the reduced mRNAs 
set (Supplementary Table S3). Since the previous zipcode 
studies on β-actin suggested the possible role of stem-loop 
structures,18 we analyzed whether our 25-nt sequence pre-
dicts a stem-loop structure. The mFold web server (http://
mfold.rna.albany.edu/?q=mfold)  search  predicted  that  this 
25-nt putative zipcode sequence can assume a stem-loop 
configuration. Interestingly, the core “CTGCC” sequence and 
part of the miR-1289-binding sites are predicted to be located 
in this loop structure (Supplementary Figure S2). We next 
pEGFP-N1-3UTR-25nt :         ACCCTGCCGCCTGGACTCCGCCTGT
* * * * * 
pEGFP-N1-3UTR-25nt-MT1:  ACCGCATGGCCTGGACTCCGCCTGT
* * * * *
pEGFP-N1-3UTR-25nt-MT2:  ACCACTTAGCCTGGACTCCGCCTGT
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analyzed and compared the secondary structures of the four 
mutant  sequences  that  we  generated  in  this  study  using 
mFold (Supplementary Figure S2). In comparing the fold 
enrichment of the reporter mRNA in MVs:cells, it appears that 
the presence of both the “CTGCC” core sequence and part of 
the miR-1289 binding site on the loop are critical to sustain 
the twofold mRNA enrichment (Supplementary Table S4).
Discussion
MVs were first described almost three decades ago by Trams 
et  al.19  as  exfoliated  vesicles  with  ectoenzyme  activity.  In 
recent  studies,  they  have  proven  valuable  as  a  “transpar-
ent window” of biomarkers to monitor the disease status in 
patients, including cancer and neurodegenerative disorders.20 
Research in recent years has also pointed out their “cargo 
role” as a communication tool between cells in the horizon-
tal transfer of RNAs and proteins between cells.3,5,6,21 Despite 
these intensive studies, the molecular mechanism by which 
genetic materials are uploaded into and transferred by MVs is 
still unknown, although for shedding MVs RNA incorporation 
may have parallels with retrovirus budding from the plasma 
membrane.22 In the present study, we have shown that there 
is  a  zipcode-like  25-nt  sequence  which  contains  a  short 
“CTGCC” core domain on a stem-loop structure and carries 
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a miR-1289 binding site in the 3UTRs of many of the most 
enriched mRNAs in MVs derived from human primary GBM 
cells and as well as melanoma cells. Furthermore, we have 
also shown that miR-1289 binds directly to this zipcode and 
orchestrates transfer mRNAs into MVs. This zipcode sequence 
can be used to increase the levels of mRNAs into MVs.
Studies focusing on intracellular mRNA localization started 
two decades ago and specific localization of mRNAs have 
been  shown  in  various  organisms  and  systems:  budding 
yeast, Drosophila, Xenopus, and in mammalian cells including 
fibroblasts, oligodendrocytes, and neurons.14,23,24 One type of 
these mRNA–protein complexes is found in cytoplasmic foci 
called processing bodies (P-bodies), which contain untrans-
lated mRNAs and can serve as sites of mRNA degradation 
or storage.25 Another study provided a link between miRNA 
function and mammalian P-bodies, as argonaute (AGO) pro-
teins were found to be localized to mammalian P-bodies in 
a  miRNA-dependent  manner.26  miRNAs  typically  associate 
with a complex of proteins that includes a member of the AGO 
family with which they form the RNA-induced silencing com-
plex including target mRNAs.27,28 In addition, Gibbings et al. 
showed a novel cellular mRNA storage site called GW-bodies 
containing GW182 and AGO2 proteins which is distinct from 
P-bodies and can serve as a novel storage depot for miRNA-
mRNA loading.29 These studies together with our observations 
suggested that not only P- or GW-bodies, but also MVs may 
be sites of miRNA–mRNA interaction involved in suppress-
ing mRNA translation in the host cell. It remains to be inves-
tigated whether the zipcode-like sequence described in our 
study might also participate in mRNA transport into P- or GW-
bodies. Another interesting question which will require further 
investigation is whether other members of the RNA-induced 
silencing complex machinery are involved in the mRNA enrich-
ment in MVs mediated by a zipcode-like sequence.
One  of  the  earliest  studies  on  regulatory  function  of 
3′UTRs in determining the cellular localization and transla-
tion of mRNAs came from analysis of chicken β-actin mRNA. 
A 54-nt sequence in the 3′UTR of β-actin mRNA was found 
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Figure 6  Effect of miR-1289 expression on the EGFP mRNA and protein levels. (a) HEK-293T cells were transfected overnight with 
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RNA was extracted and quantitative reverse transcription (qRT)-PCR was performed for EGFP and GAPDH mRNAs. EGFP mRNA levels 
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or pre-/anti-miR-1289. Seventy-two hours after transfection cells were harvested and western blot analysis was performed with antibodies 
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to be essential and sufficient for mRNA localization to the cell 
periphery.30,31 This sequence also contains a hexanucleotide 
sequence (ACACCC), which is conserved and also forms a 
stem-loop structure in β-actin mRNA in other species.18 This 
study also suggested that the functional protein–RNA inter-
actions may depend on this stem-loop secondary structure. 
Interestingly,  the  zipcode-like  sequence  described  in  our 
study is also predicted to form a stem-loop secondary struc-
ture. Our mutation analysis showed that the core sequence of 
this zipcode, “CTGCC” is indispensable for increased trans-
port of the reporter EGFP mRNAs into MVs and functions 
most efficiently within the context of the loop structure. Our 
findings suggest that the presence of both the CTGCC core 
sequence on the loop structure and the miR-1289 binding 
site in the 3′UTR have a critical role in increasing the incor-
poration of mRNAs into MVs.
Recent studies provided similarities between biogenesis 
of shed MVs and retrovirus budding, in particular, targeting 
signals such as oligomeric proteins with plasma membrane 
anchors can deliver proteins into MVs.22,32 It remains to be 
investigated whether the zipcode-like sequence identified in 
the present study can act as a regulatory cis-element incor-
porated into the RNA-induced silencing complex with Ago 
2 to direct some mRNAs into MVs or serves as a sorting 
signal or anchor to plasma membrane proteins involved in 
MV biogenesis.
Cancer MVs studies in recent years have raised inter-
esting questions as to why tumor cells would seek to load 
particular mRNAs or miRNAs into MVs. Possible explana-
tions are that mRNAs enrichment in MVs serves as “rub-
bish containers” whereby mRNAs are eliminated from the 
host cells through the miRNA-mRNA-RNA-induced silenc-
ing complex machinery, or that they serve as “storage con-
tainers” in which mRNAs are localized and transferred to 
other cells where they can be translated into proteins. The 
latter scenario seems to be very logical for tumors cells 
which express oncogenic mRNAs and proteins, such as for 
EGFRvIII in MVs which can be transferred to and active in 
recipient cells.5–7 Perhaps, this storage mechanism is used 
to quickly initiate protein translation in recipient neighboring 
cells as a message of cancer transformation. Since MVs 
can also contain tumor suppressor miRNAs, it seems also 
possible that tumor cells may try to get rid of those miR-
NAs by transferring them in MVs. So, MV-mediated elimina-
tion or transfer of mRNAs and/or miRNAs could be used 
by tumor cells depending on the requirements of cellular 
conditions involved in tumor growth. In our study, based 
on the possible cancer-associated role(s) of the top four 
most enriched mRNAs in MVs released from GBM cells, it 
seems possible that cancer cells transfer these mRNAs to 
the other cells in which their translation might be promote 
tumorigenesis.
Among the four MV-enriched mRNAs within GBM vesicles 
are those corresponding to genes MDK, COX8C, GALR3, 
and LOC653602, the first three encode known cancer-asso-
ciated proteins. One of these enriched mRNAs is the Galanin 
receptor 3 (GALR3). Berger et al.33 has shown that both GAL 
and its specific receptors are elevated in human gliomas, 
as compared to normal tissue. Based on these findings, it 
seems highly likely that these receptors are cancer-related 
and transfer via MVs would support tumor growth through 
increasing  an  immortalized  profile  in  surrounding  stromal 
cells. This mRNA was increased in 50% in MVs derived from 
HEK-293  cells  when  the  cells  were  transfected  with  pre-
miR1289, consistent with our studies using the reporter zip-
code mRNA.
Another of the most enriched mRNA in MVs found in our 
microarray was Midkine (MK or MDK), also known as neurite 
growth-promoting factor 2, which promotes cell proliferation, 
cell migration, and angiogenesis in several types of cancer in 
culture and in vivo.34 The cancer-related activity of MK mRNA 
and protein expression are frequently elevated in many types 
of human carcinomas, including breast, lung, esophageal, 
stomach, colorectal, liver, ovary prostate, and urinary bladder 
carcinomas, as well as GBMs, neuroblastomas, and Wilms’ 
tumors.35–42 However, the MDK mRNA does not carry this zip-
code and was not enriched in MVs derived from HEK-193 
cells after transfection with pre-miR1289.
The 25-nt zipcode-like sequence elucidated in these stud-
ies corresponds to sequences within the 3′UTRs of many 
of the mRNAs enriched in MVs from GBM cells (Figure 1). 
Therefore, our sequence is not specific to one type of mRNA, 
but rather appears to represent a consensus sequence pres-
ent in the 3′UTRs of a number of mRNAs enriched in tumor 
cell MVs. Our experimental analysis showed that this 25-nt 
zipcode-like sequence results in twofold mRNA enrichment 
in MVs, as compared to their cells of origin using a reporter 
mRNA. This enrichment was only seen in two cell types and 
may not be a universal mechanism. Our MV isolation strat-
egy would result in our harvesting a variety of MV subtypes, 
including exosomes, shed MVs, and microparticles. Hence, it 
may be possible that the actual enrichment level in a subtype 
of MVs is much higher.
Discovery  of  a  zipcode-like  sequence  which  can  target 
mRNAs to MVs is important in many different aspects of MV 
dynamics. MVs are now being considered as one of the essen-
tial intercellular communication tools and little is known about 
the basic biologic mechanisms underlying this form of commu-
nication. Understanding the physiological processes behind 
the  transfer  of  RNA  messages  has  broad  ranging  implica-
tions, from developmental studies to tumorigenesis, from can-
cer gene therapy to immunological studies.11,12 An important 
aspect of this miRNA/mRNA transfer dynamic is that in some 
cases it may be a means of a cell eliminating and thereby 
decreasing  translation  of  a  specific  protein,  while  in  other 
cases it may serve to transmit miRNAs or mRNAs to recipi-
ent cells where they are active and modulate their phenotype. 
One potential approach for cancer gene therapy could be that 
this sequence can incorporated into the 3′UTR of therapeutic 
RNAs (including mRNAs, short hairpin RNAs, and noncoding 
regulatory RNAs) to enrich them in MVs, which, in turn, can 
serve as vehicles to deliver them to cells in vivo through on-site 
donor cells or through injection of loaded MVs.
Materials and Methods
Cell culture. HEK-293T cells (obtained from Dr Maria Calos, 
Stanford University, Stanford, CA) were cultured in Dulbecco’s 
modified Eagle’s medium (Cellgro; Mediatech, Manassas, VA) Molecular Therapy–Nucleic Acids
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containing 10% fetal bovine serum, 100 IU/ml penicillin. and 
100 µg/ml streptomycin. Cells are incubated at 37 °C in a 5% 
CO2 atmosphere. Cells were determined to be mycoplasma 
negative by testing with a mycoplasma detection kit (MycoAlert, 
Mycoplasma Detection Assay; Lonza, Rockland, ME).
Transfection of HEK-293T cells and MV isolation. Cultures of 
HEK-293T cells (75–80% confluent) were transfected with 7 
µg pEGFP-N1 original or derived plasmids per each 200-mm 
plate  with  Lipofectamine  2000  (Invitrogen,  Carlsbad,  CA; 
11668-019), according to manufacturer’s protocol. Six hours 
later, transfection media was removed and replaced with Dul-
becco’s modified Eagle’s medium containing 5% MV-free fetal 
bovine serum. MV-free fetal bovine serum is obtained after 
the ultracentrifugation and filtration process.5 Three days after 
transfection, MVs were isolated from a total of 39-ml cell media 
from two plates through serial centrifugation: initial centrifuga-
tion was done at 300g for 15 minutes followed by 16,000g 
for 30 minutes. Then, the supernatant was filtered through 
0.22-µm filters (Millex; Millipore, Billerica, MA) into Beckman 
Quick seal tubes. Finally, ultracentrifugation was performed at 
110,000g for 90 minutes using a 70Ti rotor (Beckman Coulter, 
Brea, CA). MVs were resuspended in 50 µl twice-filtered 1× 
phosphate-buffered saline.
miRNA overexpression and inhibition. Precursory and inhibi-
tory miRNAs used for our experiments were as follows: pre-
miR-1289 (Ambion, Foster City, CA; AM17100), pre-control 
1  (AM17110),  anti-miRNA-1289  (AM17000),  and  anti-miR 
miRNA inhibitors—negative control 1 (AM17010). Both pre-
miR and anti-miRs were used at 50 nmol/l final concentration 
for co-transfection experiments.
Total  RNA  isolation,  reverse  transcription,  and  real-time 
qPCR. We isolated total RNA from both cell pellets and MVs 
using a miRvana isolation kit (Ambion), according to manu-
facturer’s protocol. Upon elution of RNA, it was treated with 
1 µl 2U DNaseI (Ambion) in 30 µl of total reaction for 30 min-
utes at 37 °C to eliminate any residual DNA. Following the 
RNA  isolation,  complementary  DNA  was  generated  using 
Omniscript RT kit-50 (Qiagen, Valencia, CA) using 100 ng 
of total RNA from MVs or 1 µg of total RNA from cell pel-
lets, according to manufacturer’s recommendations. mRNA 
levels were quantified with Applied Biosystems 7000 series 
quantitative-PCR. GAPDH mRNA was used for normalization 
purposes. The primers used in this study were as follows: 
GALR3-forward:  5′-CATGTACGCCAGCAGCTTTA,  GALR3-
reverse:  5′-ACGGTGCCGTAGTAGCTGAG;  MDK-forward: 
 5 ′-CGGTCGCCAAAAAGAAAGAT,  MDK-reverse:  5′-GGCTCC 
AAACTCCTTCTTCC GAPDH-forward: 5′-GAAGGTGAAGG 
TCGGAGT,  GAPDH-reverse:  5′-GAAGATGGTGATGGGA 
TTTC, and EGFP-forward: 5′-CCTGAAGTTCATCTGCACCA, 
and EGFP-reverse: 5′-GGTCTTGTAGTTGCCGTCGT.
Molecular  cloning  and  site-specific  mutagenesis.  For 
microsomal enrichment assays, we used pEGFP-N1 (Clon-
tech) as the parental vector. The 3′UTR of EGFP was replaced 
with the putative 25-nt zipcode at the Afl-2 and Not-1 sites 
and mutants of this sequence were inserted at the same sites 
(Supplementary  Figure  S4).  In  order  to  maintain  mRNA 
stability, part of the 3′UTR of the original construct was main-
tained to retain the SV40 polyA addition site. The 3′UTRs of 
pEGFP-N1-3UTR-25nt, pEGFP-N1-NO3UTR, and pEGFP-
N1-3UTR-25nt-MT4 inserts were generated by oligonucleotide 
annealing, as described.43 These oligonucleotide sequences 
as follows: pEGFP-N1-3UTR-25nt (5′-GGCCGCACCCTGC-
CGCCTGGACTCCGCCTGTACAAATAAAGCAATAGCAT-
CACAAATTTCACAAATAAAGCATTTTTTTCACTGCC-3′), 
pEGFP-N1-NO3UTR  (5′-GGCCGCACAAATAAAGCAATAG-
CATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCC-3′), 
and  pEGFP-N1-3UTR-25nt-MT4  (5′-GGCCGCACCCTGC-
CGCCCTGATCGCGCCTGTACAAATAAAGCAATAGCAT-
CACAAATTTCACAAATAAAGCATTTTTTTCACTGCC-3′). 
pEGFP-N1-3UTR-25nt-MT1,  pEGFP-N1-3UTR-25nt-MT2 
and pEGFP-N1-3UTR-25nt-MT3 plasmids were derived from 
pEGFP-N1-3UTR-25nt using Quickchange site-directed muta-
genesis kit (Stratagene, Santa Clara, CA). Primer sequences 
used  in  site  directed  mutagenesis  reactions  as  follows: 
MT1  forward:  5′-CAAGTAAAGCGGCCGCACCGCATGGC-
CTGGACTCCGCCTGTACMT1  reverse:  5′-GTACAGGCG-
GAGTCCAGGCCATGCGGTGCGGCCGCTTTACTTG  MT2 
forward:  5′-CAAGTAAAGCGGCCGCACCACTTAGCCT-
GGACTCCGCCTGTAC  MT2  reverse:  5′  GTACAGGCG-
GAGTCCAGGCTAAGTGGTGCGGCCGCTTTACTTG  MT3 
forward:  5′-CCGCACCCTGCCGCCTGGATCAAGCCTGTA-
CAAATAAAGCAATAGC  MT3  reverse:  5′-GCTATTGCTTT-
ATTTGTACAGGCTTGATCCAGGCGGCAGGGTGCGG.
Western  blots.  Three  days  after  transfection,  HEK-293T 
cells  were  rinsed  with  1×  phosphate-buffered  saline  and 
harvested,  and  total  proteins  were  separated  by  pre-cast 
NuPAGE  4–12%  Bis–Tris  (Invitrogen)  polyacrylamide  gel 
electrophoresis. Then proteins were transferred onto nitrocel-
lulose membranes; membranes were blocked with 5% non-
fat dry milk in phosphate-buffered saline containing 0.05% 
Tween-2044  overnight  at  4  °C. The  antibodies  used  were: 
monoclonal EGFP (1:5,000; Invitrogen; 33-2600) and β-actin 
(1:5,000; Sigma, St Louis, MO; A5356). Bands were visual-
ized using the ECL system according to instructions provided 
by the supplier (Amersham, Buckinghamshire, UK).
Luciferase miRNA target reporter assay. For the validation of 
the miR-1289 binding site in the putative MV zipcode, we used 
the pMir-Report system (Ambion, AM5795), as described.45 
In this system, the 3′UTR of firefly luciferase (Fluc) gene was 
replaced either with the putative MV zipcode or the MT1289 
mutated  version  of  this  zipcode.  DNA  oligonucleotides 
were synthesized as sense and antisense templates of the 
25-nt sequence and the mutant sequence. Then, they were 
annealed and cloned into pMir-Report between the HindIII 
and  SpeI  sites.  The  oligonucleotides  used  in  these  stud-
ies were as follows: 25-nt zipcode-UTR (5′-CTAGTACCCT-
GCCGCCTGGACTCCGCCTGTA-3′)  25-nt  zipcode-MT4: 
(5′-CTAGTACCCTGCCGCCCTGATCGCGCCTGTA-3′).
HEK-293T  cells  are  co-transfected  with  pMir-Report 
vectors and either pre-miR-1289 or pre-miR negative con-
trol 1. Two days after transfection, cells were lysed and the 
luciferase  activity  was  measured.  Another  plasmid  with  a 
Renilla luciferase (Rluc) expression cassette was co-trans-
fected and used for normalization.45www.moleculartherapy.org
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Multiple sequence alignment and zipcode scanning. The list 
of 50 most enriched and most reduced mRNAs in MVs as 
compared to GBM cells were generated from microarray data 
of Skog et al.5 The 3′UTR sequences of the top enriched 20 
genes were aligned using the multiple sequence alignment 
tool ClustalW (Clustal W2-http://www.clustal.org/) under the 
following conditions: fast alignment method, gap open 10, gap 
extend 0.2, and DNA weight matrix ClustalW. In addition, for 
deep alignment we used a slow alignment method. In order to 
eliminate false negative hits, we excluded polyA sequences in 
the 3′ ends of the sequences. Sequence similarities were found 
through pairwise alignment option of the BLAST (BLAST-http://
blast.ncbi.nlm.nih.gov/Blast.cgi). The nucleotide blast (blastn) 
program was used with minimum hit length of 7 nt.
miRNA-binding site predictions. miRNA targeting sequences 
within the 25-nt putative MV zipcode were checked using 
miRBase (http://www.mirbase.org/). Predicted target tran-
scripts of miR-1289 were collected and combined from three 
different miRNA databases: TargetScanHuman (http://www.
targetscan.org/), miRNA.org, and miRWalk (www.ma.uni-
heidelberg.de). In addition, blastn was used to detect addi-
tional similarities which were 7 base pairs or longer.
The microarray data have been deposited in NCBI’s Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) 
with GEO series accession number GSE35444.
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